The TRIUMPH Trials: Retatrutide's Investigational Evidence
TRIAL-000013
Part of the DietApp.com GLP-1 Trial Database, a comprehensive, regularly reviewed resource.
What It Is
TRIUMPH is the Phase 3 clinical trial program for retatrutide, Eli Lilly's investigational triple hormone receptor agonist (GLP-1, GIP, and glucagon). Retatrutide is not yet FDA-approved, and TRIUMPH is the evidence program that will determine whether and when it becomes available.
Key Results
TRIUMPH-1, the pivotal Phase 3 obesity trial, showed 28.3% average weight loss at 80 weeks in 2,339 participants, among the highest results reported for any obesity medication in development. In a 104-week extension, participants with a BMI of 35 or higher reached up to 30.3% average weight loss, with no plateau observed, meaning weight loss was still continuing at the point of measurement.
Beyond Weight Loss
A nested substudy within TRIUMPH-1 examining participants with obstructive sleep apnea found a 60.6% reduction in the apnea-hypopnea index from a severe baseline, a substantial finding given Zepbound's existing OSA approval was built on a similar mechanism-of-action premise, weight loss reducing airway obstruction.
Where the Program Stands
As of mid-2026, three Phase 3 programs under the TRIUMPH and related TRANSCEND-T2D umbrella have reported positive topline results, covering obesity and type 2 diabetes. An NDA filing is expected in late 2026, with realistic FDA approval more likely in 2027 to 2028 given the standard review timeline for a new molecule. Retatrutide remains legally available only through clinical trial enrollment until approved.
References
- Eli Lilly and Company: TRIUMPH-1 Phase 3 Topline Results (May 2026)
- Jastreboff AM et al., Retatrutide Phase 2 Data, NEJM
Related Resources
Related Articles
How TRIUMPH Compares to Tirzepatide's SURMOUNT Program
| Trial | Duration | Real Weight Loss Result |
|---|---|---|
| TRIUMPH-1 | 80 weeks | 28.3% average |
| TRIUMPH-1 extension (BMI 35+) | 104 weeks | Up to 30.3%, no plateau observed |
| SURMOUNT-1 (tirzepatide, for comparison) | 72 weeks | Up to ~22.5% |
See DietApp's SURMOUNT Trials page for tirzepatide's own weight-management evidence, and SURMOUNT-OSA for the sleep apnea findings that parallel retatrutide's own OSA substudy.
Frequently Asked Questions
Is retatrutide definitely more effective than tirzepatide? Trial data so far shows higher average results, but these come from different, separate trial populations, not a direct head-to-head study.
Can I get retatrutide through a clinical trial right now? Possibly, check ClinicalTrials.gov directly for currently recruiting sites.
When will retatrutide actually be available? Not confirmed; an NDA filing is expected late 2026, with realistic approval more likely 2027-2028 given standard review timelines.
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Download DietApp.com to track your own progress alongside the evidence behind your treatment.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
Last medically reviewed and updated: July 11, 2026.
Related
triumph-trials-retatrutide